Longitudinal analysis of individual cfdna methylome patterns in metastatic prostate cancer
Silva R, Moran B, Baird AM, O'Rourke CJ, Finn SP, McDermott R, Watson W, Gallagher WM, Brennan DJ, Perry AS. Clinical Epigenetics (2021) |
Integrating inflammatory serum biomarkers into a risk calculator for prostate cancer detection
Jalali A, Kitching M, Martin K, Richardson C, Murphy TB, FitzGerald SP, Watson RW, Perry AS. Scientific Reports (2021) |
Development of a Multivariable Risk Model Integrating Urinary Cell DNA Methylation and Cell-Free RNA Data for the Detection of Significant Prostate Cancer.
Connell SP, O'Reilly E, Tuzova A, Webb M, Hurst R, Mills R, Zhao F, Bapat B, Cooper CS, Perry AS, Clark J, Brewer DS. The Prostate (2020) |
Evaluating liquid biopsies for Methylomic profiling of prostate cancer.
|
Holding a Mir ror up to the robustness of the prostate cancer urinary transcriptome.
Connor AE, Jordan AC, Perry AS. Translational Andrology and Urology (2019) |
A four-group urine risk classifier for predicting outcome in prostate cancer patients.
Connell SP, Hanna M, McCarthy F, Hurst R, Webb M, Curley H, Walker H, Mills R, Ball RY, Sanda MG, Pellegrini KL, Patil D, Perry AS, Schalken J, Pandha H, Whitaker H, Dennis N, Stuttle C, Mills IG, Guldvik I. BJU International (2019) |
EpiCapture: A Urine DNA Methylation Test for Early Detection of Aggressive Prostate Cancer
O'Reilly E, Tuzova AV, Walsh AL, Russell NM, O'Brien O, Kelly S, Dhomhnallain ON, DeBarra L, Dale CM, Brugman R, Clarke G, Schmidt O, O'Meachair S, Patil D, Pellegrini KL, Fleshner N, Garcia J, Zhao F, Finn S, Mills R, Hanna MY, Hurst R, McEvoy E, Gallagher WM, Manecksha RP, Cooper CS, Brewer DS, Bapat B, Sanda MG, Clark J, Perry AS. JCO Precision Oncology (2019) |
A urine-based DNA methylation assay, procure, to identify clinically significant prostate cancer
Zhao F, Olkhov-Mitsel E, Kamdar S, Jeyapala R, Garcia J, Hurst R, Hanna MY, Mills R, Tuzova AV, O'Reilly E, Kelly S, Cooper C; Movember Urine Biomarker Consortium, Brewer D, Perry AS, Clark J, Fleshner N, Bapat B. Clinical Epigenetics (2018) |
Integrating biomarkers across OMIC platforms: An approach to improve stratification of patients with indolent and aggressive prostate cancer.
Murphy K, Murphy BT, Boyce S, Flynn L, Gilgunn S, O'Rourke CJ, Rooney C, Stöckmann H, Walsh AL, Finn S, O'Kennedy RJ, O'Leary J, Pennington SR, Perry AS, Rudd PM, Saldova R, Sheils O, Shields DC, Watson RW. Molecular Oncology (2018) |
Analysis of urinary PSA glycosylation is not indicative of high-risk prostate cancer.
Barrabés S, Llop E, Ferrer-Batallé M, Ramírez M, Aleixandre RN, Perry AS, de Llorens R, Peracaula R. International Journal of Clinical Chemistry (2017) |
Improving multivariable prostate cancer risk assessment using the prostate health index.
Foley RW, Gorman L, Sharifi N, Murphy K, Moore H, Tuzova AV, Perry AS, Murphy TB, Lundon DJ, Watson RW. BJU International (2016) |
Noncoding RNAS in prostate cancer: The long and the short of it.
Bolton EM, Tuzova AV, Walsh AL, Lynch T, Perry AS. Clinical Cancer Research (2013) |
Prostate cancer epigenetics
Perry, AS. The Journal of Urology (2013) |
The epigenome as a therapeutic target in prostate cancer
Perry AS, Watson RW, Lawler M, Hollywood D. Nature Reviews Urology (2010) |
The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer.
Murphy TM, Perry AS, Lawler M. Endocrine-Related Cancer (2008) |
The emerging roles of DNA methylation in the clinical management of prostate cancer.
Perry AS, Foley R, Woodson K, Lawler M. Endocrine-Related Cancer (2006) |